Market News & Trends
Aragen Appoints Aniel Khubchandani as CEO of Development & Manufacturing Solutions Business
Aragen recently announced the appointment of Aniel Khubchandani as CEO of its Development & Manufacturing Solutions business. Aniel will be a member of Aragen’s Management…
Sanofi Completes Acquisition of Vigil Neuroscience
Sanofi recently announced the completion of its acquisition of Vigil Neuroscience, Inc. This acquisition strengthens Sanofi’s early stage pipeline in neurology with VG-3927, a novel,…
Evoke Pharma Announces Issuance of New Patent for GIMOTI With Extended Exclusivity to Late 2038
Evoke Pharma, Inc. recently announced the official issuance of a new US patent related to its product GIMOTI. The patent, US Patent No. 12,377,064, covers…
Cardurion Pharmaceuticals Completes Enrollment in Phase 2 Trials Evaluating a Novel PDE9 Inhibitor in Heart Failure
Cardurion Pharmaceuticals, Inc. recently announced it has completed enrollment in two global, multi-center, Phase 2 clinical trials assessing the safety and efficacy of CRD-750 in…
Moleculin Biotech Reports Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Moleculin Biotech, Inc. recently announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known by its non-proprietary name of naxtarubicin, which…
Porosome Therapeutics Announces Breakthrough Alzheimer's Discoveries
Porosome Therapeutics, Inc. recently announced key advancements in its first-in-class, disease-modifying neurological platform, which will transform Alzheimer’s Disease (AD) research and treatment by offering a…
Polpharma Biologics & Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar
Polpharma Biologics S.A. recently announced a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a…
Axplora Announces Significant Investment at Vizag Site & FDA Inspection Success Across Indian Operations
Axplora recently announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience. This announcement follows the…
Elicio Therapeutics Announces Positive Recommendation to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
Elicio Therapeutics, Inc. recently announced that following the Independent Data Monitoring Committee’s (IDMC) pre-specified interim review of the unblinded safety and efficacy data in the…
Pioneering LNP Expert Dr. Pieter Cullis Joins Hongene’s Scientific Advisory Board
Hongene, a global CDMO focused on nucleic acid raw materials and medicines, has appointed Dr. Pieter Cullis, a renowned innovator in lipid nanoparticle…
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
SERB Pharmaceuticals and Y-mAbs Therapeutics, Inc. recently announced they have entered into a definitive merger agreement under which SERB will acquire Y-mAbs, including its lead…
Yatiri Bio Acquires NGeneBioAI to Expand AI-Powered Proteomics Platform & Advance Precision Biomarker Discovery
Yatiri Bio, Inc. recently announced the successful acquisition of NGeneBioAI, Inc., a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition strengthens Yatiri…
Freya Pharma Solutions Announces Launch of Phase 2 Clinical Dose-Response Study Testing its Lybrido Concept Targeting Female Sexual Dysfunction
Freya Pharma Solutions recently announced the initation of a Phase 2 clinical study evaluating its Lybrido concept. The study will investigate two dose-combinations of testosterone…
Microbiotica Announces Completion of Recruitment in its Phase 1b Trial of a Precision Microbiome Medicine in Ulcerative Colitis Patients
Microbiotica recently announced patient recruitment is complete in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international trial has…
Medicus Pharma Announces MoU With Helix Nanotechnologies to Develop Thermostable Infectious Disease Vaccines
Medicus Pharma Ltd. and Helix Nanotechnologies Inc. recently announced they have entered into a non-binding memorandum of understanding (MoU) in respect of their shared mutual interest…
HilleVax Enters Into Definitive Agreement to be Acquired by XOMA Royalty
HilleVax, Inc and XOMA Royalty Corporation recently announced they have entered into a definitive merger agreement, whereby XOMA Royalty will acquire all of the issued…
Atavistik Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ATV-1601 in Patients With AKT1 E17K-Mutant Solid Tumors
Atavistik Bio recently announced the dosing of the first patient in its Phase 1 study of ATV-1601 in adults with AKT1 E17K-mutant solid tumors. ATV-1601…
XOMA Royalty Enters Agreement to Acquire LAVA Therapeutics
XOMA Royalty Corporation and LAVA Therapeutics N.V. recently announced they have entered a definitive share purchase agreement whereby XOMA Royalty will acquire LAVA for (i)…
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety & Depression
Artelo Biosciences, Inc. recently announced that it has received written scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on the nonclinical development…
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation
Silexion Therapeutics Corp recently announced groundbreaking new preclinical data revealing unprecedented inhibition rates of up to 97% in pancreatic cancer cells and almost 90% in…
